论文部分内容阅读
目的观察阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效和安全性。方法将70例活动性乙型肝炎肝硬化患者随机分为治疗组30例和对照组40例,两组均给予常规保肝等综合治疗,治疗组在此基础上联合阿德福韦酯治疗,观察12个月。结果治疗组患者HBeAg和HBVDNA阴转率分别为93.3%和73.3%,均优于对照组的62.5%和40.0%(P<0.05),所有患者无明显的副反应。结论阿德福韦酯治疗活动性乙型肝炎肝硬化患者安全,有良好的疗效。
Objective To observe the efficacy and safety of adefovir dipivoxil in the treatment of active hepatitis B cirrhosis. Methods Seventy patients with active hepatitis B cirrhosis were randomly divided into treatment group (n = 30) and control group (n = 40). The two groups were given conventional hepatoprotective therapy. The treatment group was treated with adefovir dipivoxil, Observe for 12 months. Results The negative conversion rates of HBeAg and HBVDNA in the treatment group were 93.3% and 73.3%, respectively, which were significantly higher than those in the control group (62.5% vs 40.0%, P <0.05). No adverse reactions were observed in all the patients. Conclusions Adefovir dipivoxil is safe and effective in the treatment of patients with active hepatitis B cirrhosis.